Understanding Your Treatment Options and Starting Doses
Wegovy to Mounjaro Conversion Chart: Understanding the Key Differences
When comparing Wegovy to Mounjaro conversion options, it's essential to understand that these are distinctly different medications with unique mechanisms. Wegovy (semaglutide) is a GLP-1 receptor agonist that mimics a natural fullness hormone, whilst Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist. This fundamental difference means there isn't a direct milligram-to-milligram conversion between the two treatments. Your prescriber will evaluate your current response, medical history, and treatment goals when considering any transition between these prescription-only medicines.
The starting doses reflect these mechanistic differences in any wegovy to mounjaro conversion chart comparison. Wegovy begins with a 0.25mg weekly dose for weeks 1-4, designed to minimise initial side effects whilst allowing your body to adapt to the GLP-1 effects. Mounjaro starts at 2.5mg weekly, reflecting tirzepatide's different pharmacological profile and dual-hormone approach. Both medications require careful dose escalation under prescriber supervision, and neither starting dose should be skipped or modified without clinical guidance.
Pricing and Value: Starter Dose Investment for Both Treatments
EverydayMeds offers transparent pricing for both options in your wegovy to mounjaro conversion chart considerations. Wegovy's 0.25mg starter pen costs £79.99, providing your first month of treatment with our GPhC-registered pharmacy service (#9012878). Our Intro Duo bundle combines the 0.25mg and 0.5mg pens for £169.99, covering your first two months with convenient single delivery. New customers can apply code FIRST40 at checkout to access these prices, whilst returning customers use DOSE25.
For comparison purposes in any wegovy to mounjaro conversion chart evaluation, both treatments represent similar investment levels for comprehensive weight management support. EverydayMeds ensures you receive authentic medication with proper cold-chain storage and next-day delivery once prescribed. Our clinical assessment process, prescriber review, and ongoing support are included in these prices, providing complete treatment accessibility without hidden costs. Both Wegovy and Mounjaro are available from EverydayMeds — your prescriber can help determine which is right for you.
Clinical Evidence Supporting Wegovy to Mounjaro Conversion Chart Decisions
The STEP clinical trials provide robust evidence for Wegovy's effectiveness, with participants achieving approximately 15% average weight loss at 68 weeks when used alongside a reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). These results help inform wegovy to mounjaro conversion chart discussions by establishing semaglutide's clinical profile. The STEP programme demonstrated consistent results across different patient populations, including those with type 2 diabetes and various weight-related comorbidities.
Mounjaro's SURMOUNT trials show different efficacy patterns due to its dual-hormone mechanism, though direct comparison isn't appropriate given different trial designs and populations. When considering any wegovy to mounjaro conversion chart guidance, your prescriber will evaluate individual response patterns, tolerability, and treatment goals. Both treatments are subject to MHRA additional monitoring and require ongoing clinical supervision throughout your treatment journey.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy's mechanism as a GLP-1 receptor agonist forms the foundation for understanding any wegovy to mounjaro conversion chart comparison. Semaglutide mimics the action of GLP-1, a naturally occurring hormone that regulates appetite and food intake by acting on brain appetite centres. This mechanism promotes feelings of fullness after smaller meals, may reduce food cravings, and helps support portion control when combined with lifestyle modifications. The 0.25mg starting dose allows gradual introduction of these effects, minimising potential gastrointestinal side effects whilst building therapeutic levels. Understanding this mechanism helps explain why direct dose conversion charts between different weight management medications aren't clinically appropriate without prescriber guidance.
Ordering Process: Accessing Both Treatment Options
EverydayMeds streamlines access to both treatments featured in wegovy to mounjaro conversion chart discussions through our comprehensive three-step process. Complete our 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review your assessment within 3 working days (24-hour express service available), evaluating suitability for either Wegovy or Mounjaro based on clinical guidelines and individual factors. Once approved, your medication ships via next-day cold-chain delivery, maintaining the 2-8°C storage requirements essential for both treatments. This process ensures appropriate clinical oversight whilst providing convenient access to prescription-only weight management medications.
Storage and Practical Considerations: Treatment Management
Proper storage forms a crucial element in any wegovy to mounjaro conversion chart evaluation, as both medications require specific temperature control. Wegovy offers a storage advantage with 6 weeks room temperature stability (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both treatments arrive in their respective pen devices — Wegovy in FlexTouch pens and Mounjaro in KwikPen format — with detailed administration guidance. The mandatory dose escalation schedules differ between treatments, with Wegovy's 16-week escalation to 2.4mg maintenance requiring different planning than Mounjaro's schedule. Your prescriber will provide specific guidance on storage, administration, and dose progression relevant to your chosen treatment.
Wegovy to Mounjaro Conversion Chart: Prescriber-Led Decision Making
Professional wegovy to mounjaro conversion chart guidance requires individualised assessment rather than standardised conversion ratios. Your prescriber will evaluate your current treatment response, any side effects experienced, underlying health conditions, and personal treatment preferences when considering transitions. Factors such as injection frequency tolerance, side effect profiles, and cardiovascular considerations all influence conversion decisions. The timing of any potential switch involves careful washout periods and restart protocols specific to each medication.
EverydayMeds supports these clinical decisions through our experienced prescriber network and comprehensive patient support services. Our team understands the complexities involved in wegovy to mounjaro conversion chart planning and provides personalised guidance throughout any treatment transition. Both medications require ongoing monitoring and lifestyle support, ensuring you receive complete care regardless of your chosen treatment path.
Start Your Treatment Journey: Expert Support and Guidance
Begin your weight management journey with confidence through EverydayMeds' comprehensive service, whether you're considering Wegovy's 0.25mg starter dose or exploring wegovy to mounjaro conversion chart options. New customers use code FIRST40 at checkout for optimal pricing, whilst our experienced clinical team provides ongoing support throughout your treatment. Our GPhC-registered pharmacy (#9012878) ensures you receive authentic medication with professional oversight and convenient delivery. Visit https://everydaymeds.co.uk/products/wegovy-0-25mg to start your clinical assessment and discuss your treatment options with our qualified prescribers. Both Wegovy and Mounjaro represent significant advances in prescription weight management, and our team is here to help you navigate these options safely and effectively.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
